Humanized mice reveal a macrophage-enriched gene signature defining human lung tissue protection during SARS-CoV-2 infection
Devin Kenney, Aoife K. O’Connell, Jacquelyn Turcinovic, Paige Montanaro, Ryan Hekman, Tomokazu Tamura, Andrew R. Berneshawi, Thomas R. Cafiero, Salam Al Abdullatif, Benjamin C. Blum, Stanley I. Goldstein, Brigitte Heller, Hans P. Gertje, Esther Bullitt, Alexander J. Trachtenberg, Elizabeth Chavez, Evans Tuekam Nono, Catherine J. Morrison, Anna E. Tseng, Amira Sheikh, Susanna Kurnick, Kyle Grosz, Markus Bosmann, Maria Ericsson, Bertrand R. Huber, Mohsan Saeed, Alejandro B. Balazs, Kevin P. Francis, Alexander D. Klose, Neal Paragas, Joshua D. Campbell, John H. Connor, Andrew Emili, Nicholas A. Crossland, Alexander Ploß, Florian Douam
Abstract
The human immunological mechanisms defining the clinical outcome of SARS-CoV-2 infection remain elusive. This knowledge gap is mostly driven by the lack of appropriate experimental platforms recapitulating human immune responses in a controlled human lung environment. Here, we report a mouse model (i.e., HNFL mice) co-engrafted with human fetal lung xenografts (fLX) and a myeloid-enhanced human immune system to identify cellular and molecular correlates of lung protection during SARS-CoV-2 infection. Unlike mice solely engrafted with human fLX, HNFL mice are protected against infection, severe inflammation, and histopathological phenotypes. Lung tissue protection from infection and severe histopathology associates with macrophage infiltration and differentiation and the upregulation of a macrophage-enriched signature composed of 11 specific genes mainly associated with the type I interferon signaling pathway. Our work highlights the HNFL model as a transformative platform to investigate, in controlled experimental settings, human myeloid immune mechanisms governing lung tissue protection during SARS-CoV-2 infection.